Our apologies to those who still wince when reminded of the following figures. But because these data illustrate successes, or lack thereof, of clinical trials from the past, they serve as an outcomes baseline for the future: Will future outcomes be based on the types of protocols used in the COVID-19 vaccine trials, or will […]

The brainchild of serial biotech entrepreneur Michael Gilman, Obsidian is hoping to bring something new to the party with “on-switch” technology for a range of potential drug applications. Obsidian now has a new treasure chest to play with — and an IPO feels only a fingertip away. Obsidian closed a $115 million Series B with […]

Unlike most other industries, in science it helps to work with your friends – that’s a quote from Dr. Jonathan Rothbard, CSO of 180 Life Sciences (NASDAQ:ATNF), who joins the podcast with ATNF co-founder Prof Sir Marc Feldmann, who co-founded the company with Professor Raphael Mechoulam (known for his discovery of tetrahydrocannabinol (THC), the psychoactive part […]